Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: StealthVector (HIV) Enzo.

W Günzburg1, A M Mhashilkar, M Hindi

  • 1Institute of Molecular Virology, Gsf Munich, Ingolst Der Landstrasse 1, D-8042 Neuherberg, Germany. Walter.Guenzburg@vu-wien.ac.at

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.

Cancer gene therapy·2013
Same author

Green fluorescent protein retroviral vector : generation of high-titer producer cells and virus supernatant.

Methods in molecular medicine·2011
Same author

mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members.

Cancer gene therapy·2005
Same author

Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo.

Gene therapy·2003
Same author

Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes.

Gene therapy·2002
Same author

Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas.

International journal of cancer·2001

Enzo Biochem is developing StealthVector, an antisense gene therapy, to inhibit human immunodeficiency virus-1 (HIV-1) replication. Phase I trials began in 1998, targeting key HIV-1 gene expression regions for potential AIDS treatment.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Virology

Background:

  • Human immunodeficiency virus-1 (HIV-1) replication poses a significant challenge for effective treatment.
  • Intracellularly expressed antiviral genes offer a potential strategy for gene therapy against HIV-1.
  • Enzo Biochem is exploring antisense gene technology for therapeutic applications.

Purpose of the Study:

  • To investigate the potential of antisense genes for HIV-1 gene therapy.
  • To develop and test the efficacy of StealthVector technology for inhibiting HIV-1 replication.

Main Methods:

  • Enzo Biochem's subsidiary, Enzo Therapeutics, utilized StealthVector technology.
  • StealthVector comprises independent antisense sequences targeting two functional HIV-1 regions (TAR and tat/rev).

Related Experiment Videos

  • Phase I clinical trials were initiated in July 1998.

    • Main Results:

    • StealthVector targets HIV-1 gene expression regulation shortly after infection.
    • The technology localizes primarily in the cell nucleus for maximum effectiveness.
    • The approach aims to inhibit viral growth through targeted gene expression regulation.

    Conclusions:

    • Antisense gene therapy using StealthVector shows promise for inhibiting HIV-1 replication.
    • Nuclear localization of StealthVector enhances its potential efficacy in gene therapy for acquired immunodeficiency syndrome (AIDS).
    • Further development and trials are crucial for advancing this gene therapy approach.